Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

BACKGROUND AND AIMS: Treatment pathways for ulcerative colitis (UC) and Crohn’s disease (CD) are shifting to a more individualized, risk-stratified approach. The perception is that insurance policies may not have implemented this paradigm shift, particularly regarding access to newer agents. We eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Dulai, Parambir S., Osterman, Mark T., Lasch, Karen, Cao, Charlie, Riaz, Faisal, Sandborn, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704097/
https://www.ncbi.nlm.nih.gov/pubmed/30923985
http://dx.doi.org/10.1007/s10620-019-05594-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704097/
https://www.ncbi.nlm.nih.gov/pubmed/30923985
http://dx.doi.org/10.1007/s10620-019-05594-7

Ejemplares similares